On the public citation graph

Data Mining of the Public Version of the FDA Adverse Event Reporting System

0 signed · 1138 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.165.12.1363openalex-snapshot
Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002
inferredcites →https://doi.org/10.1001/archinte.167.16.1752openalex-snapshot
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
inferredcites →https://doi.org/10.1001/archinternmed.2011.89openalex-snapshot
The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
inferredcites →https://doi.org/10.1001/jama.296.9.1086openalex-snapshot
An Educational Intervention to Improve Physician Reporting of Adverse Drug Reactions
inferredcites →https://doi.org/10.1002/ajh.21794openalex-snapshot
Use of parenteral iron products and serious anaphylactic‐type reactions
inferredcites →https://doi.org/10.1002/pds.1001openalex-snapshot
The reporting odds ratio and its advantages over the proportional reporting ratio
inferredcites →https://doi.org/10.1002/pds.1002openalex-snapshot
The reporting odds ratio versus the proportional reporting ratio: ‘deuce’
inferredcites →https://doi.org/10.1002/pds.1275openalex-snapshot
Reports of hyperkalemia after publication of RALES—a pharmacovigilance study
inferredcites →https://doi.org/10.1002/pds.1633openalex-snapshot
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect
inferredcites →https://doi.org/10.1002/pds.1643openalex-snapshot
An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system
inferredcites →https://doi.org/10.1002/pds.1742openalex-snapshot
Quantitative signal detection using spontaneous ADR reporting
inferredcites →https://doi.org/10.1002/pds.1746openalex-snapshot
Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)
inferredcites →https://doi.org/10.1002/pds.2022openalex-snapshot
A potential competition bias in the detection of safety signals from spontaneous reporting databases
inferredcites →https://doi.org/10.1002/pds.2276openalex-snapshot
Spontaneous adverse event reports of Stevens–Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications
inferredcites →https://doi.org/10.1002/pds.3320openalex-snapshot
Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)
inferredcites →https://doi.org/10.1002/pds.615openalex-snapshot
The role of databases in drug postmarketing surveillance
inferredcites →https://doi.org/10.1002/pds.668openalex-snapshot
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
inferredcites →https://doi.org/10.1002/pds.677openalex-snapshot
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
inferredcites →https://doi.org/10.1002/pds.771openalex-snapshot
Practical pharmacovigilance analysis strategies
inferredcites →https://doi.org/10.1002/sim.3241openalex-snapshot
Mixed‐effects Poisson regression analysis of adverse event reports: The relationship between antidepressants and suicide
inferredcites →https://doi.org/10.1007/s00228-005-0951-4openalex-snapshot
Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use
inferredcites →https://doi.org/10.1007/s00228-008-0475-9openalex-snapshot
Pharmacovigilance: methods, recent developments and future perspectives
inferredcites →https://doi.org/10.1007/s00228-008-0497-3openalex-snapshot
Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?
inferredcites →https://doi.org/10.1007/s00228-012-1232-7openalex-snapshot
Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database
inferredcites →https://doi.org/10.1007/s002280050466openalex-snapshot
A Bayesian neural network method for adverse drug reaction signal generation
inferredcites →https://doi.org/10.1007/s00592-011-0340-7openalex-snapshot
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
inferredcites →https://doi.org/10.1007/s11883-010-0120-9openalex-snapshot
Evidence-Based Management of Statin Myopathy
inferredcites →https://doi.org/10.1016/j.drudis.2008.12.012openalex-snapshot
Decision support methods for the detection of adverse events in post-marketing data
inferredcites →https://doi.org/10.1016/j.ijmedinf.2009.01.001openalex-snapshot
Influence of the MedDRA® hierarchy on pharmacovigilance data mining results
inferredcites →https://doi.org/10.1016/j.jbspin.2006.09.002openalex-snapshot
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods
inferredcites →https://doi.org/10.1016/j.sapharm.2010.09.001openalex-snapshot
Examination of pharmacists’ intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior
inferredcites →https://doi.org/10.1016/j.yrtph.2012.05.016openalex-snapshot
A pre-marketing ALT signal predicts post-marketing liver safety
inferredcites →https://doi.org/10.1016/s0140-6736(03)14669-7openalex-snapshot
The statin wars: why AstraZeneca must retreat
inferredcites →https://doi.org/10.1016/s0140-6736(04)17525-9openalex-snapshot
Rosuvastatin and the statin wars—the way to peace
inferredcites →https://doi.org/10.1016/s1081-1206(10)60078-6openalex-snapshot
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
inferredcites →https://doi.org/10.1038/clpt.2009.26openalex-snapshot
Time-to-Signal Comparison for Drug Safety Data-Mining Algorithms vs. Traditional Signaling Criteria
inferredcites →https://doi.org/10.1038/clpt.2010.285openalex-snapshot
Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting System
inferredcites →https://doi.org/10.1038/nbt.2113openalex-snapshot
OpenVigil—free eyeballs on AERS pharmacovigilance data
inferredcites →https://doi.org/10.1038/nbt0409-297openalex-snapshot
Making a difference
inferredcites →https://doi.org/10.1038/nbt0709-601openalex-snapshot
More eyeballs on AERS
inferredcites →https://doi.org/10.1038/sj.clpt.6100258openalex-snapshot
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
inferredcites →https://doi.org/10.1080/15360280801989401openalex-snapshot
Safety Alert for Fentanyl Buccal Tablets
inferredcites →https://doi.org/10.1093/ndt/gfh185openalex-snapshot
On the relative safety of parenteral iron formulations
inferredcites →https://doi.org/10.1093/ndt/gfi253openalex-snapshot
Update on adverse drug events associated with parenteral iron
inferredcites →https://doi.org/10.1111/j.1365-2125.2004.02203.xopenalex-snapshot
Drug‐induced pancreatitis: lessons in data mining
inferredcites →https://doi.org/10.1111/j.1365-2125.2011.04037.xopenalex-snapshot
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
inferredcites →https://doi.org/10.1111/j.1365-2125.2011.04087.xopenalex-snapshot
When to publish measures of disproportionality derived from spontaneous reporting databases?
inferredcites →https://doi.org/10.1111/j.1365-2125.2012.04185.xopenalex-snapshot
Trends of reporting of ‘serious’vs. ‘non‐serious’ adverse drug reactions over time: a study in the French PharmacoVigilance Database
inferredcites →https://doi.org/10.1111/j.1365-2710.2008.00943.xopenalex-snapshot
Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy
inferredcites →https://doi.org/10.1111/j.1445-5994.1999.tb01627.xopenalex-snapshot
Anaphylaxis following continuous 5‐fluorouracil infusion chemotherapy
inferredcites →https://doi.org/10.1111/j.1600-051x.2012.01878.xopenalex-snapshot
Drug‐induced gingival overgrowth: a study in the F rench P harmacovigilance D atabase
inferredcites →https://doi.org/10.1177/0091270009333484openalex-snapshot
Systematic Investigation of Time Windows for Adverse Event Data Mining for Recently Approved Drugs
inferredcites →https://doi.org/10.1177/009286150804200501openalex-snapshot
VigiBase, the WHO Global ICSR Database System: Basic Facts
inferredcites →https://doi.org/10.1177/1078155212457965openalex-snapshot
Cetuximab infusion reactions: French pharmacovigilance database analysis
inferredcites →https://doi.org/10.1186/1471-2105-11-s9-s7openalex-snapshot
Mining multi-item drug adverse effect associations in spontaneous reporting systems
inferredcites →https://doi.org/10.1186/1756-9966-30-93openalex-snapshot
Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
inferredcites →https://doi.org/10.1248/bpb.35.967openalex-snapshot
Adverse Event Profile of Tigecycline: Data Mining of the Public Version of the U.S. Food and Drug Administration Adverse Event Reporting System
inferredcites →https://doi.org/10.1371/journal.pone.0028124openalex-snapshot
Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
inferredcites →https://doi.org/10.1371/journal.pone.0041289openalex-snapshot
Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach
inferredcites →https://doi.org/10.1377/hlthaff.2010.1004openalex-snapshot
Despite 2007 Law Requiring FDA Hotline To Be Included In Print Drug Ads, Reporting Of Adverse Events By Consumers Still Low
inferredcites →https://doi.org/10.1517/14740338.2012.650165openalex-snapshot
Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants
inferredcites →https://doi.org/10.1517/14740338.6.6.713openalex-snapshot
Database size and power to detect safety signals in pharmacovigilance
inferredcites →https://doi.org/10.1592/phco.24.8.743.36068openalex-snapshot
Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration
inferredcites →https://doi.org/10.2146/ajhp110262openalex-snapshot
Comparison of rates of reported adverse events associated with i.v. iron products in the United States
inferredcites →https://doi.org/10.2146/ajhp120138openalex-snapshot
Caution in making inferences from FDA’s Adverse Event Reporting System
inferredcites →https://doi.org/10.2165/00002018-200023060-00004openalex-snapshot
A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database
inferredcites →https://doi.org/10.2165/00002018-200225060-00001openalex-snapshot
Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database
inferredcites →https://doi.org/10.2165/00002018-200427120-00003openalex-snapshot
Data Quality Management in Pharmacovigilance
inferredcites →https://doi.org/10.2165/00002018-200528110-00002openalex-snapshot
Perspectives on the Use of Data Mining in Pharmacovigilance
inferredcites →https://doi.org/10.2165/00002018-200629050-00003openalex-snapshot
Under-Reporting of Adverse Drug Reactions
inferredcites →https://doi.org/10.2165/00002018-200730080-00003openalex-snapshot
Physician Response to Patient Reports of Adverse Drug Effects
inferredcites →https://doi.org/10.2165/00002018-200730080-00008openalex-snapshot
Criteria Revision and Performance Comparison of Three Methods of Signal Detection Applied to the Spontaneous Reporting Database of a Pharmaceutical Manufacturer
inferredcites →https://doi.org/10.2165/00002018-200730100-00001openalex-snapshot
The Need for Definitions in Pharmacovigilance
inferredcites →https://doi.org/10.2165/00002018-200730100-00007openalex-snapshot
Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases
inferredcites →https://doi.org/10.2165/00002018-200831040-00007openalex-snapshot
Improving the Reporting of Adverse Drug Reactions
inferredcites →https://doi.org/10.2165/00002018-200932010-00002openalex-snapshot
Determinants of Under-Reporting of Adverse Drug Reactions
inferredcites →https://doi.org/10.2165/00002018-200932020-00003openalex-snapshot
Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions
inferredcites →https://doi.org/10.2165/00002018-200932020-00006openalex-snapshot
Drug-versus-Drug Adverse Event Rate Comparisons
inferredcites →https://doi.org/10.2165/00002018-200932060-00007openalex-snapshot
An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database
inferredcites →https://doi.org/10.2165/11319000-000000000-00000openalex-snapshot
Prospective Data Mining of Six Products in the US FDA Adverse Event Reporting System
inferredcites →https://doi.org/10.2165/11531850-000000000-00000openalex-snapshot
Antimicrobials and the Risk of Torsades de Pointes
inferredcites →https://doi.org/10.2165/11532310-000000000-00000openalex-snapshot
First, Catch Your Signal!
inferredcites →https://doi.org/10.2165/11538330-000000000-00000openalex-snapshot
Mapping the Safety Profile of Biologicals
inferredcites →https://doi.org/10.2165/11584390-000000000-00000openalex-snapshot
An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
inferredcites →https://doi.org/10.2165/11586990-000000000-00000openalex-snapshot
Reporting Patterns Indicative of Adverse Drug Interactions
inferredcites →https://doi.org/10.2165/11596510-000000000-00000openalex-snapshot
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones
inferredcites →https://doi.org/10.2165/11630640-000000000-00000openalex-snapshot
Drug Fever
inferredcites →https://doi.org/10.2165/1317117-200822060-00006openalex-snapshot
Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods: An empirical study based on the US FDA adverse event reporting system database
inferredcites →https://doi.org/10.2337/dc10-2412openalex-snapshot
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
inferredcites →https://doi.org/10.2522/ptj.20090251openalex-snapshot
Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists
inferredcites →https://doi.org/10.7150/ijms.4397openalex-snapshot
Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
inferredcites →https://doi.org/10.7150/ijms.4549openalex-snapshot
Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
inferredcites →https://doi.org/10.7150/ijms.8.332openalex-snapshot
Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
inferredcites →https://doi.org/10.7150/ijms.8.487openalex-snapshot
Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
inferredcites →https://doi.org/10.7150/ijms.9.33openalex-snapshot
Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4852286openalex-extracted
Tumor Necrosis Factor-Alpha Inhibitors-Induced Systemic Lupus Erythematosus: A Real-World Pharmacovigilance Study Based on the Faers Database
inferred← citeshttps://doi.org/10.2139/ssrn.4855986openalex-extracted
Pharmacoepidemiology Study of Antibody-Drug Conjugate-Associated Interstitial Lung Disease
inferred← citeshttps://doi.org/10.2139/ssrn.4866524openalex-extracted
Gastrointestinal and Skin Safety Evaluation of Pirfenidone Versus Nintedanib: An Analysis of Real-World Pharmacovigilance and Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1001/jamadermatol.2026.3075openalex-snapshot
US Food and Drug Administration’s Adverse Event Reporting System—Highly Limited for Causal Inference in Dermatology
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2026.0754openalex-snapshot
US Food and Drug Administration Sentinel Initiative and Postmarket Drug Safety Surveillance
inferred← citeshttps://doi.org/10.1002/9781394287383.ch10openalex-snapshot
Data Science and Classification of Medical Data for Pharmacovigilance
inferred← citeshttps://doi.org/10.1002/advs.75819openalex-snapshot
How Advanced Artificial Intelligence Technologies Shape Drug–Drug and Drug–Target Interaction Modeling
inferred← citeshttps://doi.org/10.1002/ajh.23938openalex-snapshot
Cardiovascular and pulmonary adverse events in patients treated with BCR ‐ ABL inhibitors: Data from the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/bcp.70677openalex-snapshot
Anti‐seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time‐to‐onset analysis
inferred← citeshttps://doi.org/10.1002/cam4.4862openalex-snapshot
Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control
inferred← citeshttps://doi.org/10.1002/cam4.6559openalex-snapshot
Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/cam4.70548openalex-snapshot
Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/cam4.71352openalex-snapshot
A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
inferred← citeshttps://doi.org/10.1002/cam4.71979openalex-snapshot
Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study
inferred← citeshttps://doi.org/10.1002/cpt.3139openalex-snapshot
Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1002/ddr.70045openalex-snapshot
A Real‐World Disproportionality Analysis of Histamine H2‐Receptors Antagonists (Famotidine): A Pharmacovigilance Study Based on Spontaneous Reports in the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/fsn3.71166openalex-snapshot
Causal Influences of Micronutrients on Anxiety: Insights From an Observational and Mendelian Randomization Analysis
inferred← citeshttps://doi.org/10.1002/gps3.70067openalex-snapshot
Antidepressant use and Parkinson's disease risk: Overall protective effect with drug‐specific variation
inferred← citeshttps://doi.org/10.1002/hkj2.70033openalex-snapshot
Drug‐induced respiratory depression in FDA Adverse Event Reporting System for 20 years
inferred← citeshttps://doi.org/10.1002/hsr2.72194openalex-snapshot
Identifying High‐Risk Medications for Drug‐Induced Dystonia: A 20‐Year Retrospective Real‐World Pharmacovigilance Study Based on FAERS
inferred← citeshttps://doi.org/10.1002/ijc.70159openalex-snapshot
Immune checkpoint inhibitor‐induced vitiligo: A large‐scale real world pharmacovigilance study
inferred← citeshttps://doi.org/10.1002/jcph.1436openalex-snapshot
Real‐World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended‐Release Case Study
inferred← citeshttps://doi.org/10.1002/jcph.2420openalex-snapshot
A Real‐World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1002/jvc2.513openalex-snapshot
Investigating Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported in association with HIV antiretroviral therapy: An analysis of the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/lary.29992openalex-snapshot
Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/lary.30923openalex-snapshot
Otolaryngologic Side Effects After COVID ‐19 Vaccination
inferred← citeshttps://doi.org/10.1002/lary.31205openalex-snapshot
Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment
inferred← citeshttps://doi.org/10.1002/lary.32061openalex-snapshot
Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists
inferred← citeshttps://doi.org/10.1002/ohn.278openalex-snapshot
Postmarketing Reporting of Paxlovid‐Related Dysgeusia: A Real‐World Pharmacovigilance Study
inferred← citeshttps://doi.org/10.1002/pds.3805openalex-snapshot
Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants
inferred← citeshttps://doi.org/10.1002/pds.4437openalex-snapshot
Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients
inferred← citeshttps://doi.org/10.1002/pds.70037openalex-snapshot
A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1002/pds.70043openalex-snapshot
Investigating the Safety Profile of Fast‐Track COVID ‐19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study
inferred← citeshttps://doi.org/10.1002/pds.70084openalex-snapshot
A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
inferred← citeshttps://doi.org/10.1002/pds.70386openalex-snapshot
Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data
inferred← citeshttps://doi.org/10.1002/pds.70474openalex-snapshot
Endothelial and Vascular Toxicity Signals Associated With Doxorubicin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
inferred← citeshttps://doi.org/10.1002/phar.1612openalex-snapshot
Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study
inferred← citeshttps://doi.org/10.1002/phar.1731openalex-snapshot
The Risk of Glioblastoma with TNF Inhibitors
inferred← citeshttps://doi.org/10.1002/phar.1832openalex-snapshot
A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile
inferred← citeshttps://doi.org/10.1002/phar.2152openalex-snapshot
Drug‐Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1002/phar.2920openalex-snapshot
Antiviral influenza treatments and hemorrhage‐related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database
inferred← citeshttps://doi.org/10.1002/prp2.1129openalex-snapshot
Evaluating adverse events in databases
inferred← citeshttps://doi.org/10.1002/prp2.70194openalex-snapshot
A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/prp2.70303openalex-snapshot
Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases
inferred← citeshttps://doi.org/10.1002/tkm2.1029openalex-snapshot
Analysis of licorice-induced pseudoaldosteronism in the Japanese Adverse Drug Event Report database
inferred← citeshttps://doi.org/10.1007/978-3-030-29196-9_22openalex-snapshot
Multi-layered Learning for Information Extraction from Adverse Drug Event Narratives
inferred← citeshttps://doi.org/10.1007/978-3-031-12398-6_7openalex-snapshot
Therapeutic Drug Monitoring (TDM) and Toxicological Studies in Alternative Biological Matrices
inferred← citeshttps://doi.org/10.1007/978-3-662-43968-5_6openalex-snapshot
Knowledge Discovery and Visualization of Clusters for Erythromycin Related Adverse Events in the FDA Drug Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/978-981-99-1284-1_26openalex-snapshot
Introduction to Pharmacoepidemiology and Its Application in Clinical Research
inferred← citeshttps://doi.org/10.1007/s00198-023-06877-6openalex-snapshot
A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1007/s00204-020-02788-1openalex-snapshot
Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
inferred← citeshttps://doi.org/10.1007/s00210-024-03763-8openalex-snapshot
Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS)
inferred← citeshttps://doi.org/10.1007/s00210-025-04481-5openalex-snapshot
Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s00210-025-04559-0openalex-snapshot
Association between atorvastatin and sarcopenia: a study based on NHANES and FAERS databases
inferred← citeshttps://doi.org/10.1007/s00210-025-04953-8openalex-snapshot
The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database
inferred← citeshttps://doi.org/10.1007/s00210-026-05075-5openalex-snapshot
Respiratory drugs and psychiatric adverse events in children and adolescents: a pharmacovigilance study based on the FAERS database
inferred← citeshttps://doi.org/10.1007/s00210-026-05100-7openalex-snapshot
Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles
inferred← citeshttps://doi.org/10.1007/s00210-026-05168-1openalex-snapshot
Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024
inferred← citeshttps://doi.org/10.1007/s00210-026-05185-0openalex-snapshot
Pharmacovigilance assessment of drug-induced hypokalemia: from systemic risk screening to multi-dataset bioinformatics analysis focused on cisplatin
inferred← citeshttps://doi.org/10.1007/s00210-026-05230-yopenalex-snapshot
Post-marketing safety surveillance and adverse event risk factors of abemaciclib: a pharmacoepidemiologic study
inferred← citeshttps://doi.org/10.1007/s00210-026-05254-4openalex-snapshot
Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s00210-026-05322-9openalex-snapshot
Safety assessment of Neulasta® (pegfilgrastim) in patients with solid tumors: a real-world adverse event analysis from the FAERS database
inferred← citeshttps://doi.org/10.1007/s00210-026-05366-xopenalex-snapshot
Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling
inferred← citeshttps://doi.org/10.1007/s00210-026-05428-0openalex-snapshot
Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database
inferred← citeshttps://doi.org/10.1007/s00210-026-05453-zopenalex-snapshot
Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study
inferred← citeshttps://doi.org/10.1007/s00210-026-05472-wopenalex-snapshot
The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database
inferred← citeshttps://doi.org/10.1007/s00210-026-05550-zopenalex-snapshot
Drug-associated cytokine release syndrome: a FAERS pharmacovigilance study with complementary transcriptomic analysis
inferred← citeshttps://doi.org/10.1007/s00210-026-05556-7openalex-snapshot
Disproportionality analysis of drug-associated tinnitus safety signals: a 43-year pharmacovigilance study
inferred← citeshttps://doi.org/10.1007/s00210-026-05630-0openalex-snapshot
Multi-method statistical signal aggregation with machine learning for severity classification of neonatal adverse drug reactions
inferred← citeshttps://doi.org/10.1007/s00210-026-05739-2openalex-snapshot
Tacrolimus combined with everolimus versus sirolimus in organ transplantation: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s00210-026-05860-2openalex-snapshot
Integration of FAERS database and network toxicology to investigate adverse drug events and potential toxicological mechanisms of triazole antifungal agents
inferred← citeshttps://doi.org/10.1007/s00210-026-05872-yopenalex-snapshot
Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00228-014-1643-8openalex-snapshot
Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system
inferred← citeshttps://doi.org/10.1007/s00228-019-02770-6openalex-snapshot
Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study
inferred← citeshttps://doi.org/10.1007/s00228-021-03175-0openalex-snapshot
Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database
inferred← citeshttps://doi.org/10.1007/s00228-025-03849-zopenalex-snapshot
Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports
inferred← citeshttps://doi.org/10.1007/s00228-025-03872-0openalex-snapshot
Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA Adverse Event Reporting System (FAERS) and implications for clinical practice
inferred← citeshttps://doi.org/10.1007/s00228-025-03895-7openalex-snapshot
Study on disproportionality in the detection of potential signals between quetiapine and diabetic ketoacidosis
inferred← citeshttps://doi.org/10.1007/s00228-025-03905-8openalex-snapshot
A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel
inferred← citeshttps://doi.org/10.1007/s00228-025-03960-1openalex-snapshot
Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies
inferred← citeshttps://doi.org/10.1007/s00228-025-03980-xopenalex-snapshot
Systematic analysis of the adverse effects of used clinical antisense oligonucleotide drugs in DMD patients based on the FAERS database
inferred← citeshttps://doi.org/10.1007/s00240-026-01989-0openalex-snapshot
Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis
inferred← citeshttps://doi.org/10.1007/s00266-020-02027-zopenalex-snapshot
Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database
inferred← citeshttps://doi.org/10.1007/s00277-024-05676-1openalex-snapshot
Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS
inferred← citeshttps://doi.org/10.1007/s00415-021-10404-0openalex-snapshot
Guillain–Barré syndrome in patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00415-026-13764-7openalex-snapshot
Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study
inferred← citeshttps://doi.org/10.1007/s00431-023-05146-2openalex-snapshot
Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s00467-025-07043-2openalex-snapshot
Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review
inferred← citeshttps://doi.org/10.1007/s00520-024-09024-xopenalex-snapshot
KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study
inferred← citeshttps://doi.org/10.1007/s00592-019-01378-7openalex-snapshot
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s00737-024-01540-3openalex-snapshot
Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS)
inferred← citeshttps://doi.org/10.1007/s00787-025-02694-wopenalex-snapshot
Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database
inferred← citeshttps://doi.org/10.1007/s10489-014-0568-3openalex-snapshot
Temporality and Context for detecting adverse drug reactions from longitudinal data
inferred← citeshttps://doi.org/10.1007/s10557-021-07157-3openalex-snapshot
A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database
inferred← citeshttps://doi.org/10.1007/s10557-024-07558-0openalex-snapshot
Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data
inferred← citeshttps://doi.org/10.1007/s10787-026-02409-wopenalex-snapshot
Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis
inferred← citeshttps://doi.org/10.1007/s10916-016-0544-zopenalex-snapshot
Using Literature-Based Discovery to Explain Adverse Drug Effects
inferred← citeshttps://doi.org/10.1007/s11096-022-01395-7openalex-snapshot
Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-022-01457-wopenalex-snapshot
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19
inferred← citeshttps://doi.org/10.1007/s11096-022-01472-xopenalex-snapshot
Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-022-01476-7openalex-snapshot
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports
inferred← citeshttps://doi.org/10.1007/s11096-022-01510-8openalex-snapshot
Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s11096-023-01556-2openalex-snapshot
Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis
inferred← citeshttps://doi.org/10.1007/s11096-023-01673-yopenalex-snapshot
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-024-01784-0openalex-snapshot
Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
inferred← citeshttps://doi.org/10.1007/s11096-024-01814-xopenalex-snapshot
Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database
inferred← citeshttps://doi.org/10.1007/s11096-025-01869-4openalex-snapshot
Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-025-01896-1openalex-snapshot
Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s11096-025-01962-8openalex-snapshot
Cardiovascular toxicities associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a pharmacovigilance study based on FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-025-01994-0openalex-snapshot
Real-world safety profile of mitomycin: signal detection and time-to-onset analysis from FDA adverse event reporting system and VigiAccess databases
inferred← citeshttps://doi.org/10.1007/s11096-025-02027-6openalex-snapshot
Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s11096-025-02041-8openalex-snapshot
Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-026-02099-yopenalex-snapshot
Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s11096-026-02103-5openalex-snapshot
Analysis of adverse event reporting with casimersen: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s11239-023-02879-7openalex-snapshot
Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
inferred← citeshttps://doi.org/10.1007/s11239-026-03395-0openalex-snapshot
Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study
inferred← citeshttps://doi.org/10.1007/s11255-026-05042-2openalex-snapshot
Assessing the real-world safety of sparsentan for immunoglobulin A nephropathy: insights from a comprehensive analysis of FAERS database
inferred← citeshttps://doi.org/10.1007/s11523-019-00632-wopenalex-snapshot
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s12012-025-10012-8openalex-snapshot
Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients
inferred← citeshttps://doi.org/10.1007/s12020-024-04112-8openalex-snapshot
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s12029-026-01534-7openalex-snapshot
Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World
inferred← citeshttps://doi.org/10.1007/s12094-019-02060-8openalex-snapshot
Multiple sclerosis outcomes after cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s12247-026-10480-7openalex-snapshot
Disproportionality Analysis of Linaclotide-Associated Adverse Events Using Individual case Safety Reports from the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s13300-018-0408-2openalex-snapshot
Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
inferred← citeshttps://doi.org/10.1007/s13300-019-0611-9openalex-snapshot
A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
inferred← citeshttps://doi.org/10.1007/s13369-021-05999-5openalex-snapshot
RETRACTED ARTICLE: Analysis and Prediction of Adverse Reaction of Drugs with Machine Learning Models for Tracking the Severity
inferred← citeshttps://doi.org/10.1007/s13555-019-00341-2openalex-snapshot
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
inferred← citeshttps://doi.org/10.1007/s40259-020-00466-3openalex-snapshot
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
inferred← citeshttps://doi.org/10.1007/s40259-021-00469-8openalex-snapshot
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1007/s40259-021-00476-9openalex-snapshot
Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
inferred← citeshttps://doi.org/10.1007/s40261-017-0574-4openalex-snapshot
Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1007/s40261-018-0668-7openalex-snapshot
Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1007/s40261-018-0724-3openalex-snapshot
Response to “Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database”
inferred← citeshttps://doi.org/10.1007/s40261-023-01320-4openalex-snapshot
Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study
inferred← citeshttps://doi.org/10.1007/s40261-026-01525-3openalex-snapshot
Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s40264-014-0163-xopenalex-snapshot
Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database
inferred← citeshttps://doi.org/10.1007/s40264-015-0278-8openalex-snapshot
Computational Approaches for Pharmacovigilance Signal Detection: Toward Integrated and Semantically-Enriched Frameworks
inferred← citeshttps://doi.org/10.1007/s40264-015-0332-6openalex-snapshot
Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database
inferred← citeshttps://doi.org/10.1007/s40264-016-0409-xopenalex-snapshot
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
inferred← citeshttps://doi.org/10.1007/s40264-017-0550-1openalex-snapshot
An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s40264-017-0624-0openalex-snapshot
Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs
inferred← citeshttps://doi.org/10.1007/s40264-022-01194-zopenalex-snapshot
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
inferred← citeshttps://doi.org/10.1007/s40264-023-01278-4openalex-snapshot
Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data
inferred← citeshttps://doi.org/10.1007/s40264-026-01730-1openalex-snapshot
Disproportionality Analysis of FAERS Data Divergence and a Systematic Review of Comparative Safety Studies: Lessons Learned from the Example of Ranitidine and Cancer Risk
inferred← citeshttps://doi.org/10.1007/s40272-023-00613-7openalex-snapshot
Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1007/s40273-015-0306-7openalex-snapshot
Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats
inferred← citeshttps://doi.org/10.1007/s40290-016-0146-6openalex-snapshot
Open Access Pharmacovigilance Databases: Analysis of 11 Databases
inferred← citeshttps://doi.org/10.1007/s40618-026-02901-8openalex-snapshot
Mining safety signals of PD-1/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database
inferred← citeshttps://doi.org/10.1007/s40801-026-00542-0openalex-snapshot
Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades
inferred← citeshttps://doi.org/10.1007/s43188-024-00256-xopenalex-snapshot
Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s43441-025-00834-7openalex-snapshot
Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events
inferred← citeshttps://doi.org/10.1007/s43441-025-00845-4openalex-snapshot
A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat
inferred← citeshttps://doi.org/10.1007/s44337-025-00501-8openalex-snapshot
A pharmacovigilance study on platinum associated cholangitis based on the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s44446-025-00020-8openalex-snapshot
Comparison of ileus risk in selected second-generation antipsychotics based on FAERS database
inferred← citeshttps://doi.org/10.1016/b978-0-12-816183-8.00003-2openalex-snapshot
Pharmacoepidemiology in the Prevention of Adverse Drug Reactions
inferred← citeshttps://doi.org/10.1016/b978-0-323-89775-4.00005-5openalex-snapshot
Systems biology and big data analytics
inferred← citeshttps://doi.org/10.1016/b978-0-443-33024-7.00009-6openalex-snapshot
Exploring databases supporting computational pharmacology and toxicology techniques: An overview
inferred← citeshttps://doi.org/10.1016/j.ajo.2016.04.022openalex-snapshot
Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration
inferred← citeshttps://doi.org/10.1016/j.ajo.2025.03.023openalex-snapshot
Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study
inferred← citeshttps://doi.org/10.1016/j.ajo.2025.05.007openalex-snapshot
Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries
inferred← citeshttps://doi.org/10.1016/j.ajo.2026.01.042openalex-snapshot
Comment On: Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists; An Examination of the FAERS Database
inferred← citeshttps://doi.org/10.1016/j.ajp.2021.102891openalex-snapshot
Selective serotonin reuptake inhibitors and manic switch: A pharmacovigilance and pharmacodynamical study
inferred← citeshttps://doi.org/10.1016/j.ajp.2025.104657openalex-snapshot
Real-world signal detection of adverse events associated with Auvelity(bupropion-dextromethorphan): A pharmacovigilance study based on the FAERS database
inferred← citeshttps://doi.org/10.1016/j.amjoto.2024.104517openalex-snapshot
Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation
inferred← citeshttps://doi.org/10.1016/j.annepidem.2013.12.009openalex-snapshot
Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis
inferred← citeshttps://doi.org/10.1016/j.aohep.2025.102156openalex-snapshot
Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004–2024)
inferred← citeshttps://doi.org/10.1016/j.apjo.2024.100104openalex-snapshot
Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1016/j.apsb.2021.05.028openalex-snapshot
Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms
inferred← citeshttps://doi.org/10.1016/j.avsg.2026.01.043openalex-snapshot
A Real-World Pharmacovigilance Study of Cilostazol Based on the Food and Drug Administration Adverse Event Reporting System: A Cross-Sectional Disproportionality Analysis
inferred← citeshttps://doi.org/10.1016/j.bbr.2021.113168openalex-snapshot
Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies
inferred← citeshttps://doi.org/10.1016/j.bja.2025.06.044openalex-snapshot
Contemporary local anaesthetic-associated adverse events and mortality: a pharmacovigilance analysis of a US reporting system
inferred← citeshttps://doi.org/10.1016/j.bone.2023.116919openalex-snapshot
Bisphosphonates-related tendinopathies and ligament disorders: Cases analysis from the U.S. Food and Drug Administration adverse event reporting system
inferred← citeshttps://doi.org/10.1016/j.cardfail.2018.04.009openalex-snapshot
WITHDRAWN: Cognition and Dementia Related Adverse Effects with Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database
inferred← citeshttps://doi.org/10.1016/j.cardfail.2018.04.010openalex-snapshot
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database
inferred← citeshttps://doi.org/10.1016/j.cca.2022.09.019openalex-snapshot
The establishment of LC-MS/MS assays-specific reference intervals for serum folates and its application in evaluating FA-supplemented folate deficiency patients: Appeals for a suitable and individualized supplementation
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.11.017openalex-snapshot
Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization
inferred← citeshttps://doi.org/10.1016/j.clinsp.2025.100727openalex-snapshot
Analysis of the relationship between antidepressants and seizures based on the food and drug administration's adverse event reporting system database
inferred← citeshttps://doi.org/10.1016/j.clinthera.2020.03.018openalex-snapshot
Signal Management in Pharmacovigilance: A Review of Activities and Case Studies
inferred← citeshttps://doi.org/10.1016/j.clinthera.2024.09.019openalex-snapshot
Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1016/j.clinthera.2024.11.007openalex-snapshot
Data Mining and Analysis for Iodinated Contrast Media Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.09.009openalex-snapshot
Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.09.010openalex-snapshot
Characterizing Fenofibrate-Related Renal and Urinary Adverse Events: A Comprehensive Analysis of FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.12.013openalex-snapshot
Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases
inferred← citeshttps://doi.org/10.1016/j.clinthera.2026.06.007openalex-snapshot
Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database
inferred← citeshttps://doi.org/10.1016/j.clnu.2021.12.012openalex-snapshot
Managing folate deficiency implies filling the gap between laboratory and clinical assessment
inferred← citeshttps://doi.org/10.1016/j.cmpb.2022.106931openalex-snapshot
Articulating target-mining techniques to disinter Alzheimer's specific targets for drug repurposing
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2015.06.003openalex-snapshot
Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2015.08.005openalex-snapshot
Reprint of “Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction”
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2017.10.034openalex-snapshot
Evaluating Casama: Contextualized semantic maps for summarization of lung cancer studies
inferred← citeshttps://doi.org/10.1016/j.cpan.2024.11.001openalex-snapshot
Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
inferred← citeshttps://doi.org/10.1016/j.cpan.2026.07.005openalex-snapshot
Real-world adverse event signals of immunotherapeutic agents in lung cancer: A pharmacovigilance data mining approach
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104398openalex-snapshot
Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.drudis.2014.07.011openalex-snapshot
Channeling postmarketing patient data into pharmaceutical regulatory systems
inferred← citeshttps://doi.org/10.1016/j.eclinm.2022.101425openalex-snapshot
Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases
inferred← citeshttps://doi.org/10.1016/j.eclinm.2025.103385openalex-snapshot
Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178103openalex-snapshot
Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178156openalex-snapshot
Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178163openalex-snapshot
Oral anticoagulant drugs and CNS-related hematomas: a pharmacovigilance analysis from the FAERS database
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178427openalex-snapshot
Association of aggression and anti-seizure medications in pediatric patients: Disproportionality analysis using the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1016/j.eplepsyres.2017.06.007openalex-snapshot
Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
showing the first 200 of 1043 · page through all 1043
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.